Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/= 18 years of age
Diagnosis of schizophrenia
Clinical stability for 16 weeks (4 months) prior to randomization
Antipsychotic treatment stability for the past 12 weeks prior to randomization
With the exception of clozapine, patients are on any of the available marketed atypical or typical antipsychotic (treatment with a maximum of two antipsychotics)
You may not be if
Has treatment resistant schizophrenia as judged by the treating physician OR have failed two trials
Evidence that patient has clinically significant uncontrolled or unstable medical disorder (e.g. cardiovascular, renal hepatic, gastrointestinal, hematologic, immunological, neurological, endocrine, metabolic or pulmonary disease)
Patient has a body mass index (BMI) of \<17 or \>40 kg/m2, respectively
Diagnosis of mental retardation or severe organic brain syndromes
In the investigator's judgment, a significant risk of suicide or violent behavior
Clareo Health | A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)
